Diabetes, Vol 48, Issue 2 241-253, Copyright © 1999 by American Diabetes Association

ARTICLES

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

SE Kahn, S Andrikopoulos and CB Verchere
Department of Medicine, University of Washington, and Veterans Affairs Puget Sound Health Care System, Seattle 98108, USA. skahn@u.washington.edu

Islet amyloid has been recognized as a pathological entity in type 2 diabetes since the turn of the century. It has as its unique component the islet beta-cell peptide islet amyloid polypeptide (IAPP), or amylin, which is cosecreted with insulin. In addition to this unique component, islet amyloid contains other proteins, such as apolipoprotein E and the heparan sulfate proteoglycan perlecan, which are typically observed in other forms of generalized and localized amyloid. Islet amyloid is observed at pathological examination in the vast majority of individuals with type 2 diabetes but is rarely observed in humans without disturbances of glucose metabolism. In contrast to IAPP from rodents, human IAPP has been shown to form amyloid fibrils in vitro. Because all human subjects produce and secrete the amyloidogenic form of IAPP, yet not all develop islet amyloid, some other factor(s) must be involved in islet amyloid formation. One hypothesis is that an alteration in beta-cell function resulting in a change in the production, processing, and/or secretion of IAPP is critical to the initial formation of islet amyloid fibrils in human diabetes. This nidus of amyloid fibrils then allows the progressive accumulation of IAPP-containing fibrils and the eventual replacement of beta-cell mass by amyloid and contributes to the development of hyperglycemia. One factor that may be involved in producing the changes in the beta-cell that result in the initiation of amyloid formation is the consumption of increased dietary fat. Dietary fat is known to alter islet beta-cell peptide production, processing, and secretion, and studies in transgenic mice expressing human IAPP support the operation of this mechanism. Further investigation using this and other models should provide insight into the mechanism(s) involved in islet amyloidogenesis and allow the development of therapeutic agents that inhibit or reverse amyloid fibril formation, with the goal being to preserve beta-cell function and improve glucose control in type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Marzban, A. Tomas, T. C. Becker, L. Rosenberg, J. Oberholzer, P. E. Fraser, P. A. Halban, and C. B. Verchere Small Interfering RNA-Mediated Suppression of Proislet Amyloid Polypeptide Expression Inhibits Islet Amyloid Formation and Enhances Survival of Human Islets in Culture Diabetes, November 1, 2008; 57(11): 3045 - 3055. [Abstract] [Full Text] [PDF]

				M. Kebede, J. Favaloro, J. E. Gunton, D. R. Laybutt, M. Shaw, N. Wong, B. C. Fam, K. Aston-Mourney, C. Rantzau, A. Zulli, et al. Fructose-1,6-Bisphosphatase Overexpression in Pancreatic {beta}-Cells Results in Reduced Insulin Secretion: A New Mechanism for Fat-Induced Impairment of {beta}-Cell Function Diabetes, July 1, 2008; 57(7): 1887 - 1895. [Abstract] [Full Text] [PDF]

				S. Zhang, H. Liu, H. Yu, and G. J.S. Cooper Fas-Associated Death Receptor Signaling Evoked by Human Amylin in Islet {beta}-Cells Diabetes, February 1, 2008; 57(2): 348 - 356. [Abstract] [Full Text] [PDF]

				H. Ghanaat-Pour, Z. Huang, M. Lehtihet, and A. Sjoholm Global expression profiling of glucose-regulated genes in pancreatic islets of spontaneously diabetic Goto-Kakizaki rats J. Mol. Endocrinol., August 1, 2007; 39(2): 135 - 150. [Abstract] [Full Text] [PDF]

				M. J. Fowler Diabetes: Magnitude and Mechanisms Clin. Diabetes, January 1, 2007; 25(1): 25 - 28. [Full Text] [PDF]

				J. J. Meier, R. Kayed, C.-Y. Lin, T. Gurlo, L. Haataja, S. Jayasinghe, R. Langen, C. G. Glabe, and P. C. Butler Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1317 - E1324. [Abstract] [Full Text] [PDF]

				A. Garcia, S. Xu, F. E. Dewhirst, P. R. Nambiar, and J. G. Fox Enterohepatic Helicobacter species isolated from the ileum, liver and colon of a baboon with pancreatic islet amyloidosis. J. Med. Microbiol., November 1, 2006; 55(Pt 11): 1591 - 1595. [Abstract] [Full Text] [PDF]

				L. Marzban, C. J. Rhodes, D. F. Steiner, L. Haataja, P. A. Halban, and C. B. Verchere Impaired NH2-Terminal Processing of Human Proislet Amyloid Polypeptide by the Prohormone Convertase PC2 Leads to Amyloid Formation and Cell Death. Diabetes, August 1, 2006; 55(8): 2192 - 2201. [Abstract] [Full Text] [PDF]

				L. Marzban, G. Trigo-Gonzalez, and C. B. Verchere Processing of Pro-Islet Amyloid Polypeptide in the Constitutive and Regulated Secretory Pathways of {beta} Cells Mol. Endocrinol., August 1, 2005; 19(8): 2154 - 2163. [Abstract] [Full Text] [PDF]

				D. Porte Jr., D. G. Baskin, and M. W. Schwartz Insulin Signaling in the Central Nervous System: A Critical Role in Metabolic Homeostasis and Disease From C. elegans to Humans Diabetes, May 1, 2005; 54(5): 1264 - 1276. [Abstract] [Full Text] [PDF]

				L. Marzban, G. Soukhatcheva, and C. B. Verchere Role of Carboxypeptidase E in Processing of Pro-Islet Amyloid Polypeptide in {beta}-Cells Endocrinology, April 1, 2005; 146(4): 1808 - 1817. [Abstract] [Full Text] [PDF]

				B. W. Koo and A. D. Miranker Contribution of the intrinsic disulfide to the assembly mechanism of islet amyloid Protein Sci., January 1, 2005; 14(1): 231 - 239. [Abstract] [Full Text] [PDF]

				S. A. Jayasinghe and R. Langen Identifying Structural Features of Fibrillar Islet Amyloid Polypeptide Using Site-directed Spin Labeling J. Biol. Chem., November 12, 2004; 279(46): 48420 - 48425. [Abstract] [Full Text] [PDF]

				E. Gur, D. Biran, N. Shechter, P. Genevaux, C. Georgopoulos, and E. Z. Ron The Escherichia coli DjlA and CbpA Proteins Can Substitute for DnaJ in DnaK-Mediated Protein Disaggregation J. Bacteriol., November 1, 2004; 186(21): 7236 - 7242. [Abstract] [Full Text] [PDF]

				I. Coronado-Pons, A. Novials, S. Casas, A. Clark, and R. Gomis Identification of iduronate-2-sulfatase in mouse pancreatic islets Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E983 - E990. [Abstract] [Full Text] [PDF]

				E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban Pioglitazone and Sodium Salicylate Protect Human {beta}-Cells against Apoptosis and Impaired Function Induced by Glucose and Interleukin-1{beta} J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5059 - 5066. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				C. Tikellis, P. J. Wookey, R. Candido, S. Andrikopoulos, M. C. Thomas, and M. E. Cooper Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat Diabetes, April 1, 2004; 53(4): 989 - 997. [Abstract] [Full Text] [PDF]

				P. H. Yu, M. Wang, H. Fan, Y. Deng, and D. Gubisne-Haberle Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KKAy mice Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E634 - E641. [Abstract] [Full Text] [PDF]

				S. Andrikopoulos, R. L. Hull, C. B. Verchere, F. Wang, S. M. Wilbur, T. N. Wight, L. Marzban, and S. E. Kahn Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E418 - E424. [Abstract] [Full Text]

				L. Marzban, G. Trigo-Gonzalez, X. Zhu, C. J. Rhodes, P. A. Halban, D. F. Steiner, and C. B. Verchere Role of {beta}-Cell Prohormone Convertase (PC)1/3 in Processing of Pro-Islet Amyloid Polypeptide Diabetes, January 1, 2004; 53(1): 141 - 148. [Abstract] [Full Text] [PDF]

				S. Zhang, J. Liu, M. Dragunow, and G. J. S. Cooper Fibrillogenic Amylin Evokes Islet {beta}-Cell Apoptosis through Linked Activation of a Caspase Cascade and JNK1 J. Biol. Chem., December 26, 2003; 278(52): 52810 - 52819. [Abstract] [Full Text] [PDF]

				H.-L. Zhao, F. M.M. Lai, P. C.Y. Tong, D.-R. Zhong, D. Yang, B. Tomlinson, and J. C.N. Chan Prevalence and Clinicopathological Characteristics of Islet Amyloid in Chinese Patients With Type 2 Diabetes Diabetes, November 1, 2003; 52(11): 2759 - 2766. [Abstract] [Full Text] [PDF]

				A. E. Butler, J. Janson, W. C. Soeller, and P. C. Butler Increased {beta}-Cell Apoptosis Prevents Adaptive Increase in {beta}-Cell Mass in Mouse Model of Type 2 Diabetes: Evidence for Role of Islet Amyloid Formation Rather Than Direct Action of Amyloid Diabetes, September 1, 2003; 52(9): 2304 - 2314. [Abstract] [Full Text] [PDF]

				R. G. Bennett, F. G. Hamel, and W. C. Duckworth An Insulin-Degrading Enzyme Inhibitor Decreases Amylin Degradation, Increases Amylin-Induced Cytotoxicity, and Increases Amyloid Formation in Insulinoma Cell Cultures Diabetes, September 1, 2003; 52(9): 2315 - 2320. [Abstract] [Full Text] [PDF]

				R. L. Hull, S. Andrikopoulos, C. B. Verchere, J. Vidal, F. Wang, M. Cnop, R. L. Prigeon, and S. E. Kahn Increased Dietary Fat Promotes Islet Amyloid Formation and {beta}-Cell Secretory Dysfunction in a Transgenic Mouse Model of Islet Amyloid Diabetes, February 1, 2003; 52(2): 372 - 379. [Abstract] [Full Text] [PDF]

				A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler {beta}-Cell Deficit and Increased {beta}-Cell Apoptosis in Humans With Type 2 Diabetes Diabetes, January 1, 2003; 52(1): 102 - 110. [Abstract] [Full Text] [PDF]

				J. G. Geisler, W. Zawalich, K. Zawalich, J. R.T. Lakey, H. Stukenbrok, A. J. Milici, and W. C. Soeller Estrogen Can Prevent or Reverse Obesity and Diabetes in Mice Expressing Human Islet Amyloid Polypeptide Diabetes, July 1, 2002; 51(7): 2158 - 2169. [Abstract] [Full Text] [PDF]

				B. O'Nuallain and R. Wetzel Conformational Abs recognizing a generic amyloid fibril epitope PNAS, January 24, 2002; (2002) 22662599. [Abstract] [Full Text] [PDF]

				E. GAZIT A possible role for {pi}-stacking in the self-assembly of amyloid fibrils FASEB J, January 1, 2002; 16(1): 77 - 83. [Abstract] [Full Text] [PDF]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				J.-M. Ye, M. Lim-Fraser, G. J. Cooney, G. J. S. Cooper, M. A. Iglesias, D. G. Watson, B. Choong, and E. W. Kraegen Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance Am J Physiol Endocrinol Metab, April 1, 2001; 280(4): E562 - E569. [Abstract] [Full Text] [PDF]

				J. Wang, J. Xu, J. Finnerty, M. Furuta, D. F. Steiner, and C. B. Verchere The Prohormone Convertase Enzyme 2 (PC2) Is Essential for Processing Pro-Islet Amyloid Polypeptide at the NH2-Terminal Cleavage Site Diabetes, March 1, 2001; 50(3): 534 - 539. [Abstract] [Full Text]

				B. L. Wajchenberg Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome Endocr. Rev., December 1, 2000; 21(6): 697 - 738. [Abstract] [Full Text]

				J. W.M. Hoppener, B. Ahren, and C. J.M. Lips Islet Amyloid and Type 2 Diabetes Mellitus N. Engl. J. Med., August 10, 2000; 343(6): 411 - 419. [Full Text] [PDF]

				H. Mulder, S. Gebre-Medhin, C. Betsholtz, F. Sundler, and B. Ahren Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes Am J Physiol Endocrinol Metab, April 1, 2000; 278(4): E684 - E691. [Abstract] [Full Text] [PDF]

				R. G. Bennett, W. C. Duckworth, and F. G. Hamel Degradation of Amylin by Insulin-degrading Enzyme J. Biol. Chem., November 17, 2000; 275(47): 36621 - 36625. [Abstract] [Full Text] [PDF]

				K. Park and C. B. Verchere Identification of a Heparin Binding Domain in the N-terminal Cleavage Site of Pro-islet Amyloid Polypeptide. IMPLICATIONS FOR ISLET AMYLOID FORMATION J. Biol. Chem., May 11, 2001; 276(20): 16611 - 16616. [Abstract] [Full Text] [PDF]

				R. Azriel and E. Gazit Analysis of the Minimal Amyloid-forming Fragment of the Islet Amyloid Polypeptide. AN EXPERIMENTAL SUPPORT FOR THE KEY ROLE OF THE PHENYLALANINE RESIDUE IN AMYLOID FORMATION J. Biol. Chem., August 31, 2001; 276(36): 34156 - 34161. [Abstract] [Full Text] [PDF]

				B. O'Nuallain and R. Wetzel Conformational Abs recognizing a generic amyloid fibril epitope PNAS, February 5, 2002; 99(3): 1485 - 1490. [Abstract] [Full Text] [PDF]